Amarin (AMRN)
(Delayed Data from NSDQ)
$1.44 USD
-0.05 (-3.36%)
Updated Jul 1, 2022 04:00 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Price, Consensus and EPS Surprise
AMRN 1.44 -0.05(-3.36%)
Will AMRN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AMRN based on the 1-3 month trading system that nearly triples the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMRN
New Strong Sell Stocks for May 13th
Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics
AMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amarin (AMRN) Q4 Earnings Top, Sales Hurt by Vascepa Generics
Amarin (AMRN) is a Top-Ranked Growth Stock: Should You Buy?
Why Amarin (AMRN) is a Top Momentum Stock for the Long-Term
Other News for AMRN
Amarin: Constantly Living In Interesting Times
Tracking Baker Brothers Portfolio - Q1 2022 Update
REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo
Amarin extends losses after Stat report on cardiovascular therapy
New analysis of Amarin`s Vascepa resurrects effectiveness questions, STAT says